Company news
Soleno Therapeutics, Inc. news in 2023
Soleno Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 6, 2023
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome
November 5, 2023
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
October 3, 2023
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium
October 3, 2023
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 1, 2023
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
September 27, 2023
Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
September 26, 2023
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
September 25, 2023
Soleno Therapeutics to Present at the Cantor Global Healthcare Conference
September 24, 2023
Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors
August 15, 2023
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 7, 2023
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 8, 2023
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
May 2, 2023
Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days
March 27, 2023
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
March 20, 2023
Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 6, 2023
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome
January 25, 2023
Decks in 2023
- Investor Presentation (July 2023)
Investor deck · 33 slides · Jul 10, 2023